Clinical management of cardiac amyloidosis

This chapter discusses the thromboembolic and arrhythmic risk and heart failure management. Atrial fibrillation is the most prevalent arrhythmia and portends a high risk of embolic events, for which the use of anticoagulant therapy is always recommended. Sudden cardiac death may be due to the development of advanced conduction disease as well as ventricular arrhythmias, although our ability to predict these events remains weak. Once heart failure develops, loop diuretics are the mainstay treatment, whereas other heart failure medications recommended by guidelines should be tailored with caution.